Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1838]

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrozole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrazole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

ecancermedicalscience editor's choice for May 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for May 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Targeted Intraoperative radiotherapy plus lumpectomy non-inferior to EBRT in...

Prof Jayant Vaidya - University College London, London, UK

Targeted Intraoperative radiotherapy plus lumpectomy non-inferior to EBRT in preventing breast cancer recurrence ( Prof Jayant Vaidya - University College London, London, UK )

Final results of the HeartSpare study using the voluntary breath-hold technique...

Dr Frederick Bartlett - The Royal Marsden, London, UK

Final results of the HeartSpare study using the voluntary breath-hold technique treating breast cancer ( Dr Frederick Bartlett - The Royal Marsden, London, UK )

Comment: ESTRO 2015 highlights

Dr Phillip Poortman - ESTRO President

Comment: ESTRO 2015 highlights ( Dr Phillip Poortman - ESTRO President )

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Metastatic triple-negative breast cancer responds to immunotherapy ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant...

Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA )

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

PARP inhibitor combo shows early promise for patients with and without BRCA...

Dr Timothy Yap - Royal Marsden Hospital, London, UK

PARP inhibitor combo shows early promise for patients with and without BRCA mutations ( Dr Timothy Yap - Royal Marsden Hospital, London, UK )

More from ecancer